Skip to main content

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and / or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)

Trial Status: Complete

The purpose of this open-label, 2:1 randomized phase III trial is to compare the safety and efficacy of talazoparib (also known as BMN 673) versus protocol-specific physician's choice in patients who have locally advanced and / or metastatic breast cancer with germline BRCA mutations.

Inclusion Criteria

  • Histologically or cytologically confirmed carcinoma of the breast
  • Locally advanced breast cancer that is not amenable to curative radiation or surgical cure and/or metastatic disease appropriate for systemic single cytotoxic chemotherapy
  • Documentation of a deleterious, suspected deleterious, or pathogenic germline BRCA1 or BRCA2 mutation from Myriad Genetics or other laboratory approved by the Sponsor
  • No more than 3 prior chemotherapy-inclusive regimens for locally advanced and/or metastatic disease (no limit on prior hormonal therapies or targeted anticancer therapies such as mechanistic target of rapamycin (mTOR) or CDK4/6 inhibitors, immune-oncology agents, tyrosine kinase inhibitors, or monoclonal antibodies against CTL4 or VEGF)
  • Prior treatment with a taxane and/or anthracycline in the neoadjuvant, adjuvant, locally advanced, or metastatic setting unless medically contraindicated
  • Have measurable or non-measurable, evaluable disease by the revised response evaluation criteria in solid tumors (RECIST) v.1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

Exclusion Criteria

  • First-line locally advanced and/or metastatic breast cancer with no prior adjuvant chemotherapy unless the Investigator determines that one of the 4 cytotoxic chemotherapy agents in the control arm would otherwise be offered to the subject
  • Prior treatment with a PARP inhibitor (not including iniparib)
  • Not a candidate for treatment with at least 1 of the treatments of protocol-specific physician's choice (ie, capecitabine, eribulin, gemcitabine, vinorelbine)
  • Subjects who had objective disease progression while receiving platinum chemotherapy administered for locally advanced or metastatic disease; subjects who received low-dose platinum therapy administered in combination with radiation therapy are not excluded
  • Subjects who have received platinum in the adjuvant or neoadjuvant setting are eligible; however, subjects may not have relapsed within 6 months of the last dose of prior platinum therapy
  • Cytotoxic chemotherapy within 14 days before randomization
  • Radiation or anti-hormonal therapy or other targeted anticancer therapy within 14 days before randomization
  • HER2 positive breast cancer
  • Active inflammatory breast cancer
  • CNS metastases
  • Exception: Adequately treated brain metastases documented by baseline CT or MRI scan that has not progressed since previous scans and that does not require corticosteroids (except prednisone ≤ 5 mg/day or equivalent) for management of CNS symptoms. A repeat CT or MRI following the identification of CNS metastases (obtained at least 2 weeks after definitive therapy) must document adequately treated brain metastases.
  • Subjects with leptomeningeal carcinomatosis are not permitted
  • Prior malignancy except for any of the following:
  • Prior BRCA-associated cancer as long as there is no current evidence of the cancer
  • Carcinoma in situ or non-melanoma skin cancer
  • A cancer diagnosed and definitively treated ≥ 5 years before randomization with no subsequent evidence of recurrence
  • Known to be human immunodeficiency virus positive
  • Known active hepatitis C virus, or known active hepatitis B virus
  • Known hypersensitivity to any of the components of talazoparib


Los Angeles
Translational Research In Oncology - US Inc (TRIO-US)
Status: ACTIVE
UCLA / Jonsson Comprehensive Cancer Center
Palo Alto
Stanford Cancer Institute Palo Alto
San Francisco
UCSF Medical Center-Mount Zion


University of Colorado Hospital


Indiana University / Melvin and Bren Simon Cancer Center


Kansas City
University of Kansas Cancer Center
University of Kansas Cancer Center-West
Status: ACTIVE
Overland Park
University of Kansas Cancer Center-Overland Park
Status: ACTIVE


University of Maryland / Greenebaum Cancer Center
Status: ACTIVE


Ann Arbor
University of Michigan Comprehensive Cancer Center


Kansas City
The University of Kansas Cancer Center-South
Status: ACTIVE
University of Kansas Cancer Center - North
Status: ACTIVE
Lee's Summit
University of Kansas Cancer Center - Lee's Summit
Status: ACTIVE

New York

New York
Laura and Isaac Perlmutter Cancer Center at NYU Langone


University of Pittsburgh Cancer Institute (UPCI)


M D Anderson Cancer Center

Trial Phase Phase III

Trial Type Treatment

Lead Organization
Pfizer Inc

  • Primary ID 673-301
  • Secondary IDs NCI-2014-00659, 2013-002716-28, C3441009, s14-00495, U1111-1155-7579
  • ID NCT01945775